|
Class of Bcl-2 Inhibitors as Anti-Cancer Therapeutics
Application
Small molecule inhibitors of Bcl-2, an anti-apoptotic protein, for cancer treatment.
Key Benefits
Developed specifically to target the BH4 homology domain of Bcl-2 in order to improve binding affinity and anti-tumor efficacy over other Bcl-2 inhibitors.
Compounds may simultaneously suppress a wider range of anti-apoptotic proteins...
Published: 4/24/2024
Contributor(s): Xingming Deng, Jia Zhou, Chunyong Ding
|
|
Bax Activators as Highly Selective Anti-Tumor Agents
Application
Therapeutic for treatment of cancer.
Key Benefits
The first in class, potent and selective agonists of Bax with nanomolar activity.
Bax activators have significantly less apoptotic effect on normal cells as compared to cancer cells.
Compounds have shown high selectivity for tumor cells.
Technical Summary
Patients with cancer have...
Published: 4/23/2024
Contributor(s): Xingming Deng, Jia Zhou, Chunyong Ding
|
|
Small Molecule for Treatment-Resistant Lung Cancer
Application
Small molecule agonist for treating cancers involving KRAS mutations.
Key Benefits
Specifically targets mutant KRAS in non-small-cell lung carcinoma (NSCLC).
Selective for mutant KRAS lung cancer cells over normal cells.
Non-toxic to normal cells.
Market Summary
Lung cancer patients with KRAS mutation(s) have a poor prognosis due...
Published: 4/23/2024
Contributor(s): Xingming Deng
|
|
Small Molecule Inhibitors of Mcl-1 as Anti-Cancer Agent
Application
Myeloid cell leukemia 1 (Mcl-1) inhibitor to enhance DNA replication stress sensitivity for cancer therapy.
Key Benefits
Inhibits DNA repair in cancer cells.
Used in combination with existing cancer therapy.
Market Summary
Chemoresistance occurs when cancer cells develop resistance to chemotherapy drugs, and appearance of chemoresistance...
Published: 4/24/2024
Contributor(s): Xingming Deng, Guo Chen, Abu Syed Md Anisuzzaman
|